CoChat

Prolonged Suppression of Corticosteroid-Binding Globulin by Recombinant Human Interleukin-6 in Man

Open access
Tsigos, C. · 1998 · Journal of Clinical Endocrinology & Metabolism
Cited by 50

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Corticosteroid-binding globulin (CBG), a glucoprotein of hepatic origin, binds cortisol and modifies its bioavailability (1). Interleukin-6 (IL-6) dose-dependently inhibits CBG messenger RNA expression and protein secretion by hepatoblastoma-derived (HepG2) cells (2). This is consistent with the presence of a nuclear factor-IL-6-binding site in the rat CBG gene promoter, also conserved in the promoter of the human CBG gene (3). These findings suggest that CBG is a negative acute phase reactant protein. We recently reported the results of a dose-response study of single subcutaneous injections of recombinant human IL-6 on pituitary hormone production and glucose metabolism in healthy male volunteers (4, 5). We hereby provide evidence from these volunteers that supports the inhibitory effect of IL-6 on CBG production. We measured CBG (6), cortisol, and the positive acute phase reactant C-reactive protein (CRP) at baseline, then at 24 h, 48 h, and 7 days after the IL-6 injection in three volunteers who received 0.3 μg/kg of IL-6, a dose that did not activate the hypothalamic-pituitary-adrenal (HPA) axis and in three volunteers who received 3.0 μg/kg of IL-6, a dose that strongly stimulated the HPA axis (4). Plasma IL-6 levels reached a peak of 22 ± 5 pg/mL and 290 ± 38 pg/mL for the two doses respectively, between 2 and 4 h after the injection, and returned to baseline by 24 h in both groups. While the 0.3 μg/kg dose did not appreciably influence plasma CBC levels, the 3.0 μg/kg dose caused a significant and persistent decrease in CBC levels that lasted at least 48 h, but returned to baseline by 7 days (Fig. 1).The corresponding CRP levels showed a mirror image response, increasing significantly by 24 h (from 0.77 ± 0.06 mg/dL to 9.8 ± 1.01 mg/dL, P < 0.01), remaining elevated at 48 h (6.0 ± 1.24, P < 0.05 vs. baseline) and returning to normal by 7 days (0.75 ± 0.05 mg/dL). Cortisol levels, despite the dramatic response observed during the first 4 h after the IL-6 injection (4), were at baseline by 24 h and remained so thereafter. It is of note that the plasma IL-6 concentrations reached after the 3.0μ g/kg dose are within the range of plasma IL-6 concentrations previously reported in septic patients or during acute trauma and surgery (7, 8) and that CBG levels are dramatically decreased in such patients, suggesting that hepatic production of CBG is inhibited. The in vitro data of Emptoz-Bonneron et al. (2) and our findings in healthy humans suggest that IL-6 is a regulator of CBG production and, hence, a determinant of cortisol bioavailability. Mean ± se plasma CBG responses to the two doses (0.3 and 3.0 μg/kg) of recombinant human IL-6 administration. * P < 0.02 by paired t-test. Mean ± se plasma CBG responses to the two doses (0.3 and 3.0 μg/kg) of recombinant human IL-6 administration. * P < 0.02 by paired t-test.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.83.9.3379

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 50

Metadata

Authors
Tsigos, C.
Venue
Journal of Clinical Endocrinology & Metabolism
Published
1998-09-01
Volume
83
Issue
9
Pages
3379-3379
ISSN
0021-972X (ISSN-L)
OpenAlex
W1984660882
Cited by
50
References
5
FWCI
1.63
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.